{"created":"2015-05-15T13:08:10+00:00","modified":"2015-05-15T13:08:10+00:00","valid":{"from":"2013-05-22T08:37:04+00:00","to":"3013-05-22T08:37:04+00:00"},"hreflang":"en","guid":"9e8db4d5-95cd-4af2-87bb-cce23546be54","tags":["APM","Health Care","Medicare","pharmaceuticals","prescription"],"byline":"D Gorenstein","contenttemplated":"[{\"content\":\"<p>Later today, a U.S. Senate committee is scheduled to hold a hearing on the prescription drug benefit program for seniors known as Medicare Part D.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>The program has been around now for 10 years. And it has meant tens of millions of new customers for pharmaceutical companies says <a href=\\\"https://bepp.wharton.upenn.edu/profile/1670/contact\\\">Mark Duggan</a>, an economist at the University of Pennsylvania.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>“It expanded insurance coverage to many elderly and disabled <a href=\\\"http://www.marketplace.org/tags/medicare\\\" target=\\\"_blank\\\">Medicare</a> recipients, who otherwise wouldn’t have that coverage,” says Duggan. “But on the other hand, the plans that Medicare recipients joined were very effective at negotiating price discounts.”</p>\"},{\"type\":\"text/html\",\"content\":\"<p>Duggan says the Part D plans, which are run by insurance companies, have steered patients to generics. He says that’s helped keep down the cost of prescription drugs. Spending increases have slowed from 11 percent a year to less than 4 percent.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>Yale economist <a href=\\\"http://mba.yale.edu/faculty/profiles/scottmorton.shtml\\\">Fiona Scott Morton</a> says the emphasis on cheaper drugs has pushed companies to be more innovative if they want a big payday. </p>\"},{\"type\":\"text/html\",\"content\":\"<p>“It forces firms to think about what can I invent that&apos;s not just a me-too drug. But is something that breaks new ground,” she says.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>Still, Scott Morton says thanks to Part D, drug makers are selling their products to millions more Americans than they were 10 years ago.</p>\"}]","contentencoded":"<div class=\"barn-cleaned\"><p>Later today, a U.S. Senate committee is scheduled to hold a hearing on the prescription drug benefit program for seniors known as Medicare Part D.</p>\n<p>The program has been around now for 10 years. And it has meant tens of millions of new customers for pharmaceutical companies says <a href=\"https://bepp.wharton.upenn.edu/profile/1670/contact\">Mark Duggan</a>, an economist at the University of Pennsylvania.</p>\n<p>“It expanded insurance coverage to many elderly and disabled <a href=\"http://www.marketplace.org/tags/medicare\" target=\"_blank\">Medicare</a> recipients, who otherwise wouldn’t have that coverage,” says Duggan. “But on the other hand, the plans that Medicare recipients joined were very effective at negotiating price discounts.”</p>\n<p>Duggan says the Part D plans, which are run by insurance companies, have steered patients to generics. He says that’s helped keep down the cost of prescription drugs. Spending increases have slowed from 11 percent a year to less than 4 percent.</p>\n<p>Yale economist <a href=\"http://mba.yale.edu/faculty/profiles/scottmorton.shtml\">Fiona Scott Morton</a> says the emphasis on cheaper drugs has pushed companies to be more innovative if they want a big payday.&nbsp;</p>\n<p>“It forces firms to think about what can I invent that's not just a me-too drug. But is something that breaks new ground,” she says.</p>\n<p>Still, Scott Morton says thanks to Part D, drug makers are selling their products to millions more Americans than they were 10 years ago.</p></div>","published":"2013-05-22T08:37:04+00:00","description":"The prescription drug plan has created millions of senior customers for the pharmaceutical industry over ten years.","title":"How Medicare Part D changed the drug industry","teaser":"The prescription drug plan has created millions of senior customers for the pharmaceutical industry over ten years.","itags":["9e8db4d595cdaf2c7bbbcce23546be54","PMP:Marketplace_PMP","Marketplace Morning Report for Wednesday, May 22, 2013","Marketplace","Marketplace Morning Report"],"audio":[{"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/56616300.jpg?itok=xj-9Rbjv","type":"image/jpeg","meta":{"width":"610","crop":"primary","height":"340"}},{"meta":{"api":{"type":"application/json","href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2013/05/22/marketplace_segment04_20130522"},"duration_hms":"00:01:23","duration":83},"format":"MP3","type":"audio/mpeg","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2013/05/22/marketplace_segment04_20130522_64.mp3"}]}